A Phase 4 interventional study of Median nerve electrical stimulation treatment and Huperzine A injection in Cognitive Impairment After Brain Injury, sponsored by Wanbangde Pharmaceutical Group Co., LTD. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Wanbangde Pharmaceutical Group Co., LTD · Phase 4, Interventional, and Treatment
This study will conduct a single-center clinical trial to explore the initial therapeutic effect of ginkgo biloba dropping pills, huperzine A injection and median nerve electrical stimulation in patients with cognitive impairment.
Specific experimental research methods were randomized, controlled, single-center, exploratory clinical study, through the treatment of ginkgo biloba dropping pills, huperzine A injection and median nerve electrical stimulation in patients with cognitive impairment, to observe the effects of their neuroprotection and cognitive function improvement.
Wanbangde Pharmaceutical Group Co., LTD is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The optimal median nerve electrical stimulation treatment was given
Other: Median nerve electrical stimulation treatment
Huperzine A injection can be administered before median nerve electrical stimulation to improve the therapeutic effect of electrical stimulation. Huperzine A injection: intramuscular injection, 1ml,0.2mg once a day, the course of treatment was 7 days.
Other: Median nerve electrical stimulation treatment · Drug: Huperzine A injection
Huperzine A injection can be administered before median nerve electrical stimulation to improve the therapeutic effect of electrical stimulation. After the end of the electrical stimulation treatment, ginkgo biloba dropping pills were given as long-term administration to maintain the therapeutic effect. Huperzine A injection: intramuscular injection, 1ml,0.2mg once a day, the course of treatment was 7 days. Ginkgo leaf dropping pills: Oral, each pill weighs 63mg, 5 pills/time, 3 times/day, the course of treatment is 3 months.
Other: Median nerve electrical stimulation treatment · Drug: Huperzine A injection · Drug: Ginkgo leaf dropping pill
Median nerve electrical stimulation is an electrical stimulation therapy in which the electrode is placed at the median nerve point 2cm above the carpal wrinkles on the palmar surface of the wrist joint. Generally, the right median nerve is used for electrical stimulation. Electrical stimulation improves cognitive function by stimulating neurons in the brain and improving information transmission between neurons. When electrical current stimulates the brain, it can increase the activity level of neurons and promote the signal transmission between neurons. Its mechanism of action includes the regulation of neurotransmitter acetylcholine, thereby enhancing cognitive function.
intramuscular
oral
to assess the Mini-Mental State Examination (MMSE) score
Mini-Mental State Examination (MMSE): total score ranges from 0 to 30. Higher scores indicate better cognitive function.
Time frame: baseline，Day10，Day90
to assess the Montreal Cognitive Assessment (MoCA) score
Montreal Cognitive Assessment (MoCA): total score ranges from 0 to 30. Higher scores indicate better cognitive function.
Time frame: baseline，Day10，Day90
to assess the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-cog) score
Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog): total score ranges from 0 to 70. Higher scores indicate worse cognitive performance.
Time frame: baseline，Day10，Day90
to assess the Hamilton Depression Rating Scale (HAMD) score
Hamilton Depression Rating Scale (HAMD-24 item): total score ranges from 0 to 76. Higher scores indicate more severe depressive symptoms.
Time frame: baseline，Day10，Day90
to assess the Hamilton Anxiety Rating Scale (HAMA) score
Hamilton Anxiety Rating Scale (HAMA): total score ranges from 0 to 56. Higher scores indicate more severe anxiety symptoms.
Time frame: baseline，Day10，Day90
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wanbangde Pharmaceutical Group Co., LTD